Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 32

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials

Liang, Liang, Huang, Yabing, Xu, Rong, Wei, Yanyan, Xiao, Ling, Wang, Gaohua · 2019 · Sleep Medicine

Abstract

STUDY OBJECTIVE In this study, we performed a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials to evaluate the efficacy and safety of eszopiclone for the treatment of primary insomnia. METHODS We searched MEDLINE, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials and PubMed from inception to June 2018. Additionally, we searched the ClinicalTrials.gov trials register for other relevant trials. According to participants, intervention, comparison, outcome (PICO) criteria, studies were included that focused on: adults diagnosed with primary insomnia, aged 18-65 and > 65 years; eszopiclone for the treatment of primary insomnia; comparison were made between eszopiclone and placebo; as well as primary outcomes, secondary outcomes, and adverse effects. RESULTS A total of six randomized trials involving 2809 patients with primary insomnia were included in our analysis. Our analysis suggested that eszopiclone was associated with significant improvements in subjective sleep latency, wake after sleep onset, number of awakenings, total sleep time at one week, two weeks, one month, three months and six months. Meanwhile, eszopiclone was associated with increased quality of sleep, ability to function, daytime alertness and sense of physical well-being at one week, one month, three months and six months. Dizziness and unpleasant taste were the most common adverse effects in elderly subgroup. Alternately, non-elderly patients may be more prone to adverse effects such as infection, pharyngitis, somnolence, unpleasant taste and dry mouth. CONCLUSION This meta-analysis showed that eszopiclone is an effective and safe therapy option for patients with primary insomnia, especially in elderly patients. However, due to the high clinical heterogeneity in some outcomes, further standardized preparation, large-scale and rigorously designed trials are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.sleep.2019.03.016

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 26

  1. Ohayon, 2002, Epidemiology of insomnia: what we know and what we still need to learn, Sleep Med Rev, 6, 97, 10.1053/smrv.2002.0186 · DOI · Paper page
  2. Wilt, 2016, Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American college of physicians, Ann Intern Med, 165, 103, 10.7326/M15-1781 · DOI · Paper page
  3. Benca, 2005, Diagnosis and treatment of chronic insomnia: a review, Psychiatr Serv, 56, 332, 10.1176/appi.ps.56.3.332 · DOI · Paper page
  4. McCrae, 2007, Eszopiclone for late-life insomnia, Clin Interv Aging, 2, 313
  5. Owen, 2011, Eszopiclone: an update on its use in insomnia, Drugs Today, 47, 263, 10.1358/dot.2011.47.4.1590792 · DOI
  6. Wessell, 2005, Eszopiclone (Lunesta) for treatment of transient and chronic insomnia, Am Fam Phys, 71, 2359
  7. Rosenberg, 2005, An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults, Sleep Med, 6, 15, 10.1016/j.sleep.2004.09.001 · DOI
  8. Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, Ann Intern Med, 151, W65, 10.7326/0003-4819-151-4-200908180-00136 · DOI · Paper page
  9. Uchimura, 2012, A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia, Sleep Med, 13, 1247, 10.1016/j.sleep.2012.08.015 · DOI
  10. Shamseer, 2015, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation, BMJ, 350, g7647, 10.1136/bmj.g7647 · DOI · Paper page
  11. Pichot, 1986, DSM-III: the 3d edition of the diagnostic and statistical manual of mental disorders from the American psychiatric association, Revue neurologique, 142, 489
  12. Kasahara, 1981, DSM-III (diagnostic and statistical manual of mental disorders, the 3d edition), a new diagnostic criteria in the United States, Seishin shinkeigaku zasshi Psychiatria et neurologia Japonica, 83, 607
  13. Slee, 1978, The international classification of Diseases: ninth revision (ICD-9), Ann Intern Med, 88, 424, 10.7326/0003-4819-88-3-424 · DOI · Paper page
  14. Ebner, 2018, From meta-analysis to Cochrane reviews, J Cachexia Sarcopenia Muscle, 9, 441, 10.1002/jcsm.12312 · DOI
  15. Riley, 2013, Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data, Stat Med, 32, 2747, 10.1002/sim.5726 · DOI
  16. Krystal, 2003, Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia, Sleep, 26, 793, 10.1093/sleep/26.7.793 · DOI · Paper page
  17. McCall, 2006, A polysomnography study of eszopiclone in elderly patients with insomnia, Curr Med Res Opin, 22, 1633, 10.1185/030079906X112741 · DOI
  18. Zammit, 2004, Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia, Curr Med Res Opin, 20, 1979, 10.1185/174234304X15174 · DOI · Paper page
  19. Ancoli-Israel, 2010, A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia, Sleep, 33, 225, 10.1093/sleep/33.2.225 · DOI
  20. Scharf, 2005, A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia, Sleep, 28, 720, 10.1093/sleep/28.6.720 · DOI
  21. Buscemi, 2005, The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis, J Gen Intern Med, 20, 1151, 10.1111/j.1525-1497.2005.0243.x · DOI · Paper page
  22. Ferracioli-Oda, 2013, Meta-analysis: melatonin for the treatment of primary sleep disorders, PLoS One, 8, 10.1371/journal.pone.0063773 · DOI · Paper page
  23. Owen, 2011, Eszopiclone: an update on its use in insomnia, Drugs Today (Barc), 47, 263, 10.1358/dot.2011.47.4.1590792 · DOI
  24. Barbone, 1998, Association of road-traffic accidents with benzodiazepine use, Lancet, 352, 1331, 10.1016/S0140-6736(98)04087-2 · DOI · Paper page
  25. Verster, 2006, Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test, Curr Drug Saf, 1, 63, 10.2174/157488606775252674 · DOI
  26. Uemura, 2015, Residual effects of zolpidem, triazolam, rilmazafone and placebo in healthy elderly subjects: a randomized double-blind study, Sleep Med, 16, 1395, 10.1016/j.sleep.2015.05.021 · DOI

Cited by

See all 32

Metadata

Authors
Liang, L., Huang, Y., Xu, R., Wei, Y., Xiao, L., & Wang, G.
Venue
Sleep Medicine
Publisher
Elsevier BV
Published
2019-10
Volume
62
Pages
6-13
ISSN
1389-9457
Cited by
32
References
4
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. https://app.cochat.ai/papers/10.1016/j.sleep.2019.03.016
The paper
Liang, L., Huang, Y., Xu, R., Wei, Y., Xiao, L., & Wang, G. (2019). Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. Sleep Medicine. https://doi.org/10.1016/j.sleep.2019.03.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.